SCHEDULE 13G/A 0001172661-24-002826 0001281446 XXXXXXXX LIVE 2 Common Stock, par value $0.001 per share 12/31/2024 0001766140 Unicycive Therapeutics, Inc. 90466Y103 4300 El Camino Real Suite 210 Los Altos CA 94022 Rule 13d-1(c) Great Point Partners, LLC DE 0.00 11473166.00 0.00 11473166.00 11473166.00 N 9.99 IA OO Dr. Jeffrey R. Jay, M.D. X1 0.00 11473166.00 0.00 11473166.00 11473166.00 N 9.99 HC IN Ms. Lillian Nordahl X1 0.00 11473166.00 0.00 11473166.00 11473166.00 N 9.99 HC IN Unicycive Therapeutics, Inc. 4300 El Camino Real, Suite 210, Los Altos, CA 94022 Great Point Partners, LLC Dr. Jeffrey R. Jay, M.D. Ms. Lillian Nordahl The Reporting Persons have entered into a Joint Filing Agreement, dated February 14, 2025, a copy of which is filed with this SCHEDULE 13G/A as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act. The address of the principal business office of each of the Reporting Persons is 165 Mason Street, 3rd Floor Greenwich, CT 06830 Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Ms. Lillian Nordahl is a citizen of the United States. Y 11,473,166 9.99 0 11,473,166 0 11,473,166 The information required by Items 4(a) - (c) is set forth in Rows (5) - (11) of the cover pages for the Reporting Persons and is incorporated herein by reference. The percentage set forth in Row (11) of the cover pages for the Reporting Persons are based on a total of 114,353,347 shares outstanding, received from the issuer on January 10, 2025 and 493,166 shares of the Common Stock issuable upon conversion of Preferred Stock held by the reporting persons (subject to the Beneficial Ownership Cap). Biomedical Value Fund, L.P. ("BVF") is the record holder of 6,503,000 shares of Common Stock (the "BVF Shares"). Such shares constitute 5.66% of the shares of Common Stock outstanding, computed in accordance with Rule 13d-3. BVF is the record holder of Preferred Stock to convert an additional 1,777,000 shares of Common Stock (the "BVF Preferred"). As a result of the Beneficial Ownership Cap, 292,119 shares underlying such Preferred Stock are convertible, which constitutes 0.25% of the shares of Common Stock outstanding, computed in accordance with Rule 13d-3. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as Senior Managing Member of Great Point, and Ms. Lillian Nordahl ("Ms. Nordahl"), as Managing Director of Great Point, has voting and investment power with respect to the BVF Shares, and therefore may be deemed to be the beneficial owner of the BVF Shares. Biomedical Offshore Value Fund, Ltd. ("BOVF") is the record holder of 4,477,000 shares of Common Stock (the "BOVF Shares"). Such shares constitute 3.90% of the shares of Common Stock outstanding, computed in accordance with Rule 13d-3. BOVF is the record holder of Preferred Stock to convert an additional 1,223,000 shares of Common Stock (the "BOVF Preferred"). As a result of the Beneficial Ownership Cap, 201,047 shares underlying such Preferred Stock are convertible, which constitutes 0.18% of the shares of Common Stock outstanding, computed in accordance with Rule 13d-3. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as Senior Managing Member of Great Point, and Ms. Lillian Nordahl ("Ms. Nordahl"), as Managing Director of Great Point, has voting and investment power with respect to the BOVF Shares, and therefore may be deemed to be the beneficial owner of the BOVF Shares. Notwithstanding the above, Great Point, Dr. Jay and Ms. Nordahl disclaim beneficial ownership of the BVF Shares and the BOVF Shares, except to the extent of their respective pecuniary interests. 1. Great Point Partners, LLC (a) Amount beneficially owned: 11,473,166 (b) Percent of class: 9.99 (c) Number of shares as to which the person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 11,473,166 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 11,473,166 2. Dr. Jeffrey R. Jay, M.D. (a) Amount beneficially owned: 11,473,166 (b) Percent of class: 9.99 (c) Number of shares as to which the person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 11,473,166 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 11,473,166 3. Ms. Lillian Nordahl (a) Amount beneficially owned: 11,473,166 (b) Percent of class: 9.99 (c) Number of shares as to which the person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 11,473,166 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 11,473,166 In addition to an aggregate of 10,980,000 shares of the Issuer's common stock (the "Common Stock") held outright, the reporting persons hold in the aggregate preferred stock (the "Preferred Stock") that may convert into an additional 3,000,000 shares of Common Stock. However, the provisions of such Preferred Stock restrict the conversion of such Preferred Stock to the extent that, after giving effect to such conversion, the holder of the Preferred Stock and its affiliates, together with any other person or entities with which such holder would constitute a group, would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion (the "Beneficial Ownership Cap"). As a result, 493,166 shares underlying such Preferred Stock are beneficially owned by the reporting persons. Based on a total of 114,353,347 shares outstanding, received from the issuer on January 10, 2025 and 493,166 shares of the Common Stock issuable upon conversion of Preferred Stock held by the reporting persons (subject to the Beneficial Ownership Cap). Y N See Item 4. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the SCHEDULE 13G/A to which this Exhibit is attached, and such SCHEDULE 13G/A is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such SCHEDULE 13G/A and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. Dated: February 14, 2025 Great Point Partners, LLC By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D., as Senior Managing Member Dr. Jeffrey R. Jay, M.D. By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D. Ms. Lillian Nordahl By: /s/ Ms. Lillian Nordahl Ms. Lillian Nordahl Great Point Partners, LLC /s/ Dr. Jeffrey R. Jay, M.D 02/14/2025 Dr. Jeffrey R. Jay, M.D. /s/ Dr. Jeffrey R. Jay, M.D 02/14/2025 Ms. Lillian Nordahl /s/ Ms. Lillian Nordahl 02/14/2025